GlassScriptPhysician profile
Javed Asif Sayed
NPI 1164867974
$8,227.06
in general payments reported to CMS, 2019-2025
24 companies · $910 in 2025
The $910 reported for 2025 was more than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $743 · 2020: $72.41 · 2021: $556 · 2022: $1,555 · 2023: $2,376 · 2024: $2,015 · 2025: $910.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,711 · Honoraria: $1,390 · Consulting Fee: $1,200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,711.31 |
| Honoraria | $1,390.00 |
| Consulting Fee | $1,200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alimera Sciences, INC. | $2,505.50 | 2020-2024 | Iluvien, Yutiq |
| Beaver-Visitec International, INC. | $1,200.00 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $686.43 | 2019-2024 | Eylea Hd |
| Genentech USA, INC. | $612.49 | 2020-2025 | Vabysmo, Susvimo |
| Carl Zeiss Meditec USA, INC. | $419.78 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $411.87 | 2019-2020 | |
| Ani Pharmaceuticals, INC. | $382.27 | 2024-2025 | Purified Cortrophin Gel, Iluvien, Yutiq |
| Allergan, INC. | $325.23 | 2019-2021 | |
| Abbvie INC. | $308.26 | 2022-2025 | Ozurdex |
| Astellas Pharma US INC | $273.91 | 2023-2024 | Izervay |
| Apellis Pharmaceuticals, INC. | $192.13 | 2022-2025 | Syfovre |
| Regeneron Pharmaceuticals, INC. | $186.22 | 2021-2023 | Eylea |
| Sun Pharmaceutical Industries INC. | $125.88 | 2023-2025 | Cequa |
| Genentech, INC. | $122.04 | 2025 | Vabysmo |
| The Cameron-Ehlen Group, INC. | $109.21 | 2023 | Tecnis Iol, Healon Pro, Tecnis Simplicity |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma Global Development | $91.34 | 2025 | Izervay |
| Harrow Eye, LLC | $51.60 | 2024-2025 | Vevye |
| Mallinckrodt Hospital Products INC. | $50.96 | 2024 | Acthar |
| Biogen, INC. | $47.17 | 2022-2023 | |
| Bausch & Lomb Americas INC. | $33.74 | 2022-2024 | Xiidra |
| Coherus Oncology, INC. | $27.36 | 2023 | |
| Eyepoint US, INC. | $26.35 | 2020-2022 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Oyster Point Pharma, INC. | $17.92 | 2023 | Tyrvaya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Javed Sayed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.